Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 First-in-Human Study of Amivantamab (EGFR/MET bispecific antibody) in Advanced NSCLC
jRCT2080224108Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of amivantamab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting toxicities of amivantamab (± lazertinib or chemotherapy) and Maximum tolerated dose (MTD) / Recommended Phase 2 dose (RP2D, RP2CD). Started Oct 2018; status: completed.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224108.